In accord with this, FXR has been identified as a potential mediator of the rapidly beneficial metabolic effects of bariatric surgery in mice9, and initial clinical results indicate that FXR agonists may have beneficial effects in non-alcoholic fatty liver disease and the metabolic syndrome10, 11. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.